Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical transplant with IL-15-stimulated NK cell infusion for refractory pediatric solid tumors
2009-010186-23Phase 2Active
- Sponsor
- Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús
- Start
- Feb 2009
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of IL-15-stimulated NK cells in Nonhematologic neoplasms, Not applicable, lymphoma and 3 more, sponsored by Fundación para la Investigación Biomédica Hospital Universitario Niño Jesús. Primary endpoint: Primary safety endpoint. Started Feb 2009; status: active.
02
Drugs
IL-15-stimulated NK cells
03
Conditions
Nonhematologic neoplasmsNot applicablelymphomaneuroblastomarhabdomyosarcoma (RMS)
Beyond the preview
Go deeper on 2009-010186-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010186-23.